Colon Cancer DOT
The goals of researchers and clinicians in the Colon Team
- Find defective cell functions that lead to gastrointestinal (GI) cancers
- Develop unique treatments for patients with advanced colorectal cancer
- Characterize inherited risk factors that lead to GI cancers
- Develop animal models of GI cancers
Research that Makes a Difference
A Clinical Trial to Test a New Drug
Nearly 40% of patients with advanced colorectal cancer have tumors that contain a gene mutation called KRAS. A clinical trial designed by Huntsman Cancer Institute investigator Dr. Garrido-Laguna evaluates how standard chemotherapy reacts with a drug called MEK162 to block molecules from signaling a cancer-causing pathway. In this study, HCI investigator Dr. Andrea Bild will evaluate a gene signature that predicts which pathways are activated and the cells’ response to MEK162.
Looking at the Gut to Develop Better Treatment
Microbiomes are bacteria that live and work in partnership with the body. A research project by the Colon Team examines the relationship between microbial communities found in the gut and new drug treatment. Researchers study how the microbiomes react to chemotherapy or immunotherapy so they can create more effective treatments for patients.
The Need for Healthy Controls in Cancer Studies
In all scientific experiments, a control group is a key part of
Patient Education and Support Program
For people discovering that they, or members of their family, are at increased risk of developing cancer, the knowledge can be devastating. The Colon Team focuses on providing patient-friendly education and support that will empower people to manage their health. In collaboration with Huntsman Cancer Foundation, the Colon Team will initiate a Patient Day educational event. This will be a year-long program with regular group meetings.